CBD and Kidney Disease: Drug Interactions Guide 2026

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Medical Disclaimer: This article covers specific drug interactions with verified clinical significance. It is for educational purposes only. It does not constitute medical advice, clinical guidance, or recommendations from Kidney Disease and Hypertension Centers, PA or its physicians. Kidney transplant patients, patients on immunosuppressants, and patients with CKD must consult their transplant nephrologist and pharmacist before using any CBD product. Do not modify any medication regimen based on this content. KidneyDiseaseMS.com is an independent health research publication, not a medical practice.

By KidneyDiseaseMS.com Editorial Team

Quick Answer: CBD inhibits cytochrome P450 enzymes CYP3A4 and CYP2C19. For kidney transplant patients, this creates a clinically documented interaction with tacrolimus and cyclosporine — the immunosuppressants used to prevent organ rejection. Published case reports document approximately a threefold increase in tacrolimus blood concentrations with concurrent CBD use. Elevated calcineurin inhibitor levels cause drug toxicity; insufficient levels risk rejection. CBD also interacts with warfarin (via CYP2C9), certain calcium channel blockers (via CYP3A4), and likely with sirolimus and everolimus. Any CBD use in a kidney patient requires explicit nephrologist and pharmacist review of the complete medication list.

Who This Safety Briefing Is For

This guide is written for adults managing kidney disease who are evaluating CBD supplements and need a clear, sourced account of what the drug interaction data actually shows — not a disclaimer paragraph that mentions “consult your doctor” as a formality. The CYP3A4 interaction risk is specific, quantified in published literature, and directly relevant to the medications most commonly prescribed in this patient population.

The interactions documented here apply regardless of which CBD product is used, regardless of dose, and regardless of whether the product is labeled full-spectrum or THC-free. The CYP3A4 inhibition mechanism is a property of CBD as a compound, not a product-specific characteristic. It affects transplant patients most acutely. It also affects a broader population of CKD patients on medications metabolized through these pathways.

For readers who have already read our endocannabinoid system overview, this article goes deeper into the pharmacological mechanisms. For readers coming to this topic from a specific CBD product review, this article provides the interaction context that product reviews cannot cover in adequate depth. See also our companion safety resource covering nootropic supplements for related CYP3A4 interaction patterns: nootropic supplements and kidney disease safety.

Calcineurin Inhibitors: The Highest-Priority Interaction

Tacrolimus (brand name Prograf) and cyclosporine (brand names Sandimmune, Neoral) are calcineurin inhibitors — the immunosuppressant drugs most commonly used to prevent organ rejection after kidney transplantation. Both are narrow-therapeutic-window medications: the difference between a therapeutic dose and a toxic dose is small, and maintaining stable blood concentrations is an active clinical management task requiring regular monitoring.

Both tacrolimus and cyclosporine are primarily metabolized by cytochrome P450 3A4 (CYP3A4) and transported by P-glycoprotein (P-gp). CBD inhibits both CYP3A4 and CYP2C19, and published evidence suggests it may also inhibit P-glycoprotein. When CBD inhibits CYP3A4, tacrolimus and cyclosporine are cleared from the bloodstream more slowly. Blood concentrations rise. If the patient and their transplant team are not monitoring for this change, drug toxicity can develop before anyone recognizes the cause.

The clinical documentation for this interaction is not theoretical. A case report published in the American Journal of Transplantation documented a participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus. The participant showed approximately a three-fold increase in dose-normalized tacrolimus concentrations while receiving CBD at doses of 2000-2900mg daily. The report characterized this as a clinically significant drug-drug interaction and raised a specific concern for the transplant community. A separate report published in Transplantation documented an interaction between CBD, cyclosporine, and mycophenolate mofetil in a 50-year-old patient with end-stage kidney disease who had received a renal transplant. These case reports represent the first documented clinical evidence of these interactions and are the basis for the current clinical guidance from transplant pharmacists: disclose all CBD use to your transplant team immediately.

mTOR Inhibitors: Sirolimus and Everolimus

Not every kidney transplant patient receives tacrolimus or cyclosporine as their primary calcineurin inhibitor. Some patients are managed with mTOR inhibitors, such as sirolimus (Rapamune) or everolimus (Zortress), as primary or adjunctive immunosuppression. Both sirolimus and everolimus are also primary substrates of CYP3A4 and P-glycoprotein. The interaction mechanism with CBD is identical to that documented for calcineurin inhibitors: CBD's inhibition of CYP3A4 reduces clearance, potentially leading to elevated blood concentrations.

There are not published case reports specifically documenting CBD-sirolimus or CBD-everolimus interactions as of 2026, likely because these interactions have not yet been systematically studied in that population. The absence of case reports does not mean the interaction does not exist — it means it has not yet been documented. The pharmacological basis for the interaction is the same as for tacrolimus and cyclosporine. Any patient on sirolimus or everolimus should treat CBD with the same caution as tacrolimus patients until more data are available.

Mycophenolate Mofetil

Mycophenolate mofetil (CellCept) and mycophenolic acid (Myfortic) are antiproliferative immunosuppressants commonly used alongside calcineurin inhibitors in kidney transplant regimens. The published CBD-cyclosporine-mycophenolate case report noted that CBD appeared to interact with mycophenolate mofetil as well as cyclosporine in the same patient. CBD undergoes conjugation via UDP-glucuronosyltransferase enzymes including UGT1A9 — an enzyme also involved in mycophenolate metabolism. The interaction is plausible on pharmacological grounds and documented in at least one case. Transplant patients on mycophenolate should discuss this interaction with their pharmacist when evaluating any CBD product.

Antihypertensives and Blood Pressure Medications

Hypertension is near-universal in CKD, and most CKD patients are on at least one antihypertensive medication. Some of the most commonly used antihypertensives are metabolized through CYP3A4, creating an interaction pathway with CBD.

Calcium channel blockers — including amlodipine, nifedipine, and felodipine — are CYP3A4 substrates. CBD's inhibition of CYP3A4 may reduce their clearance, potentially producing elevated blood levels and enhanced blood pressure-lowering effects. For patients already achieving adequate blood pressure control, this could produce symptomatic hypotension, dizziness, or falls. ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, irbesartan) are not primarily metabolized through CYP3A4, giving them a lower direct interaction risk with CBD. However, both CBD and antihypertensives can lower blood pressure independently, and additive hypotensive effects are possible pharmacodynamically, even in the absence of a CYP450 metabolic interaction. Any patient on antihypertensive therapy should have their medication list reviewed by their pharmacist before starting CBD.

Anticoagulants: Warfarin and DOACs

Warfarin (Coumadin) is metabolized primarily by CYP2C9. CBD inhibits CYP2C9, reducing warfarin's clearance and potentially increasing its blood concentrations. Because warfarin has a narrow therapeutic window — small increases in blood level produce clinically significant increases in bleeding risk — this interaction has been documented in case reports and is considered clinically significant. Patients taking warfarin for atrial fibrillation, prior pulmonary embolism, mechanical heart valve, or any other indication should not start CBD without explicit physician guidance and planned INR monitoring.

The direct oral anticoagulants (DOACs) — rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and dabigatran (Pradaxa) — are increasingly used in CKD and post-transplant patients. Rivaroxaban, apixaban, and edoxaban are all CYP3A4 and P-glycoprotein substrates. CBD's inhibition of these pathways may increase DOAC blood concentrations, raising bleeding risk. DOAC dose adjustments are also complicated by reduced kidney function, which affects clearance independently. CKD patients on DOACs face a layered interaction risk when considering CBD. We also cover this in Jekzo Smart Ring.

General Safety Profile for Healthy Adults Without Kidney Disease

For adults without kidney disease and not taking interacting medications, CBD is generally well-tolerated at supplemental doses in the published literature. The most commonly reported side effects from ingredient-level research include drowsiness at higher doses, dry mouth, mild digestive discomfort, and appetite changes. Liver enzyme elevations have been reported in studies using higher pharmaceutical doses; available data from studies using typical supplemental doses do not suggest a significant risk of hepatotoxicity in healthy adults. CBD does not produce the intoxication associated with THC. It is not considered physically habit-forming.

However, “generally well-tolerated in healthy adults” is a statement about a different population than kidney disease patients and transplant recipients. The general safety profile does not transfer to the clinical population of this site without qualification.

Drug Test Interference

Full-spectrum CBD products contain trace THC. Even at levels below 0.3% by dry weight (the prior legal threshold), trace THC can accumulate with daily use and produce a positive result on a urine drug screen. This is a practical concern for patients subject to drug testing — including some patients in pre-transplant evaluation or monitored post-transplant programs. CBD isolate products are manufactured to remove THC, but labeling accuracy in this category is inconsistent, and some products marketed as THC-free have been found to contain detectable THC levels in third-party testing. Any patient subject to drug testing who is considering CBD should use a third-party tested, certified THC-free product and disclose use to the testing administrator before screening.

When to Consult a Physician Before Starting Any CBD Supplement

The answer for kidney patients is simple: always, and specifically before starting, not after. The transplant nephrologist and transplant pharmacist are the right resources for transplant patients. For non-transplant CKD patients, the prescribing physician and a pharmacist with access to the complete medication list are the appropriate consultants.

The consultation should include: the specific CBD product you are considering, the dose you intend to use, and a complete medication list. The pharmacist should evaluate each medication on that list for CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein interaction potential. For transplant patients, this review should happen before any CBD use begins — not after you have already started and noticed something unusual in your next lab results.

For context on what to look for in a specific CBD product before bringing it to your provider, see our product evaluation framework: CBD supplement research 2026. For a product-level review applying these considerations to one specific brand, see: Triple Green Farms CBD Gummies review 2026. For a comparison of multiple CBD products through a kidney-aware lens: CBD gummies compared 2026. For our broader endocannabinoid and kidney health context: the endocannabinoid system and kidney health 2026.

Frequently Asked Questions

Can kidney transplant patients take CBD? Not without explicit consultation with their transplant nephrologist and pharmacist. CBD inhibits CYP3A4, the enzyme metabolizing tacrolimus and cyclosporine. Published case reports document a three-fold increase in tacrolimus concentrations with concurrent CBD use. This interaction applies regardless of CBD product or dose. Disclose any CBD use to your transplant team immediately.

Does CBD interact with blood pressure medications? Potentially, yes — particularly calcium channel blockers metabolized through CYP3A4 (amlodipine, nifedipine, felodipine). CBD inhibition of CYP3A4 may reduce their clearance and enhance blood pressure-lowering effects. Complete medication list review by a pharmacist is required before starting CBD.

Does CBD interact with diuretics? The direct pharmacokinetic interaction is not well-characterized in published literature. Pharmacodynamic interactions (additive blood pressure-lowering effects) are possible. Complete medication review is appropriate before starting CBD in any CKD patient on diuretics.

Does CBD affect anticoagulants? Yes. CBD inhibits CYP2C9, which metabolizes warfarin. Published case reports document INR elevation (increased bleeding risk) with concurrent CBD-warfarin use. DOACs that are CYP3A4 substrates (rivaroxaban, apixaban, edoxaban) may also be affected. Never start CBD on anticoagulants without physician guidance and planned monitoring.

What about anti-rejection medications beyond tacrolimus and cyclosporine? Sirolimus and everolimus are also CYP3A4 substrates and face the same theoretical interaction risk. Mycophenolate mofetil has been documented in at least one case report of CBD interaction. Any transplant patient on any immunosuppressant regimen should discuss CBD with their transplant team before use.